Hematogenix

hematogenix.com

Hematogenix is an oncology diagnostic services company founded by physicians to help physicians. While we pride ourselves in the aid we provide to our clients; patient care is our priority. We exist to improve patient care, and we are dedicated to that cause. Hematogenix provides a complete menu of services such as Molecular Tumor Profiling, Flow Cytometry, FISH analysis, Cytogenetics, Molecular Diagnostics, Bone Marrow Morphology and more. Our test menu reflects our commitment to utilizing the most advanced techniques to enhance patient care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

news image

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More

INDUSTRIAL IMPACT

GINKGO BIOWORKS AND THE RWANDA DEVELOPMENT BOARD ANNOUNCE PLANS TO DEVELOP AND IMPLEMENT NEW BIOSECURITY CAPABILITIES IN RWANDA

Ginkgo Bioworks | August 12, 2022

news image

Ginkgo Bioworks the leading horizontal platform for cell programming, and the Rwanda Development Board representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding with the intent of developing and implementing new biosecurity capabilities in Rwanda. The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region. ...

Read More

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

news image

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

news image

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More
news image

CELL AND GENE THERAPY

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More
news image

INDUSTRIAL IMPACT

GINKGO BIOWORKS AND THE RWANDA DEVELOPMENT BOARD ANNOUNCE PLANS TO DEVELOP AND IMPLEMENT NEW BIOSECURITY CAPABILITIES IN RWANDA

Ginkgo Bioworks | August 12, 2022

Ginkgo Bioworks the leading horizontal platform for cell programming, and the Rwanda Development Board representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding with the intent of developing and implementing new biosecurity capabilities in Rwanda. The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region. ...

Read More
news image

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More
news image

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More